Single-cell sequencing reveals MCAM+ MyCAFs as key pro-angiogenic cells interacting with endothelial cells in solid-type adenoid cystic carcinoma Authors: Xiaotian Yuan, Yunqing Liu, Benjian Zhang, Yan Fang, Lai Meng, Zirong Chen, Hua Zhang, Yongzhen Mo, Weihong Jiang Published: 2025 ABSTRACT AbstractBackgroundSolid-type adenoid cystic carcinoma (ACC) is the most aggressive pathological type with the poorest prognosis. Extensive neovascularization and recruitment of cancer associated fibroblasts (CAFs) are the main characteristics, but the relationship between the two remains unclear.MethodsSingle-cell RNA sequencing was performed to classify and characterize CAFs in ACC. Primary CAFs from ACC were isolated and purified, and the pro-angiogenic capacity of CAFs from solid-type and non-solid-type ACC were compared. Finally, the upstream regulatory mechanisms of pro-angiogenic factor transcription were studied both in vitro and in vivo.ResultsCompared to non-solid-type ACC, CAFs in solid-type ACC are predominantly composed of melanoma cell adhesion molecule (MCAM)+ myofibroblastic cancer-associated fibroblasts (myCAFs). The transcriptional levels of pro-angiogenic factors such as platelet-derived growth factor subunit A (PDGFA), platelet-derived growth factor subunit B (PDGFB), angiopoietin-1 (ANGPT1), and angiopoietin-2 (ANGPT2) in MCAM+ myCAFs were significantly upregulated and exhibited stronger pro-angiogenic activity than MCAM− fibroblasts from non-solid-type ACC. In vivo experiments showed that MCAM+ myCAFs mixed with the ACC cell line salivary gland adenoid cystic carcinoma cell line 83 (SACC83) had a stronger tumorigenic ability and induced more abundant microvascular formation compared to the implantation of SACC83 alone. Additionally, the transcription factor myocyte enhancer factor 2 C (MEF2C) was found to bind to the promoters of PDGFA, PDGFB, ANGPT1, and ANGPT2, initiating their transcription. Knockdown of MEF2C inhibited the pro-angiogenic activity of MCAM+ myCAFs both in vitro and in vivoConclusion MCAM+ myCAFs promote the transcription of pro-angiogenic factors through MEF2C, thereby enhancing angiogenesis and promoting tumor growth in solid-type ACC.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12935-025-04103-3.Keywords: Solid-type adenoid cystic carcinoma, Cancer associated fibroblasts, MEF2C, Angiogenesis, Single-cell RNA sequencing Background Adenoid cystic carcinoma (ACC) is a malignant tumor of glandular origin characterized by a dual epithelial composition of ductal epithelial cells and myoepithelial cells, with the head and neck being one of the most common sites [1]. ACC tends to grow slowly but has a high degree of insidiousness, often being detected at an advanced stage with perineural invasion as a hallmark feature [2]. According to the WHO, ACC is classified into three histological types: tubular, cribriform, and solid [3]. Among these, the solid type ACC has the worst prognosis and is considered a high-grade transformation (HGT) type. HGT can be seen in various salivary gland cancers, including acinic cell carcinoma, secretory carcinoma, adenoid cystic carcinoma, and epithelial-myoepithelial carcinoma [3]. It is characterized by the loss of differentiation in cells, which transition from their original structure and function to an undifferentiated state. Patients with the solid type or HGT have a poor prognosis, with higher rates of recurrence within 2 years post-surgery, metastasis within 5 years post-surgery, and mortality compared to other ACC patients [4]. Currently, the internationally accepted treatment for ACC is surgical resection followed by adequate local radiotherapy [5]. Apart from conventional treatments, targeted therapies, particularly anti-angiogenic therapies, have shown promising responses in some studies; however, the reported outcomes vary [6]. At present, there is no standardized drug therapy for solid type ACC, but some molecules, such as MYB proto-oncogene, transcription factor (MYB), which are highly expressed in solid type ACC, have indicated a positive therapeutic response in some phase II clinical trials targeting tumor angiogenesis [7, 8]. Although most approved anti-angiogenic drugs have proven effective, their complex mechanisms of action are not yet fully understood. This complicates the determination of the optimal context for individualized treatment. The proposed mechanisms of action for anti-angiogenic drugs include: (1) Vessel Exhaustion: Inhibition of tumor development by blocking angiogenesis [9]; (2) Vessel Normalization: Restoration of normal function and structure of tumor vasculature to improve drug delivery [9]; (3) Immune Activation: Pro-angiogenic factors within tumors can downregulate adhesion molecules on tumor vascular endothelial cells, allowing tumors to evade infiltration by cytotoxic leukocytes [10]. Anti-angiogenic drugs could potentially overcome the downregulation of adhesion molecules and the lack of response to inflammatory signals. Currently, a Phase II clinical trial evaluated the efficacy of the VEGFR inhibitor axitinib in combination with the PD-L1 inhibitor avelumab in patients with recurrent/metastatic ACC [11]. Among the 28 evaluable patients, the study achieved its primary endpoint (Partial Response (PR) ≥ 4; Objective Response Rate (ORR) = 18%), which is significantly better than any clinical study conducted to date using anti-angiogenic therapies alone for ACC. Cancer-associated fibroblasts (CAFs) are a type of cell found within the tumor microenvironment, characterized by their heterogeneity in origin, phenotype, and function. Activated CAFs can promote tumor growth, angiogenesis, invasion and metastasis, extracellular matrix (ECM) remodeling, and even chemoresistance [12]. In various cancers, such as breast cancer and cholangiocarcinoma, CAFs have been identified as key factors involved in tumor angiogenesis and changes in endothelial function [13–15]; however, the mechanisms remain unclear. Additionally, CAFs can secrete proteins and matrix metalloproteinases, leading to ECM remodeling, altering intratumoral pressure, and indirectly affecting vascular function through modulating the exchange of substances in tumor vasculature [16]. Current studies have found that in ACC, especially in the solid subtype of ACC, the proportion of fibroblasts in the tumor microenvironment is significantly higher than that of other cell types, and there is evident neovascularization within the stroma [17]. Therefore, exploring the relationship between CAFs and angiogenesis in ACC, particularly in the solid subtype, may be crucial for understanding ACC tumor progression. Methods Clinical sample collection All human tissue and tumor samples used and collected in this study were obtained in accordance with the guidelines of the International Medical Scientific Organization and the World Health Organization. The study protocol was approved by the local ethics committee of Central South University (August 2024; 202408159). All specimens were removed or biopsied as part of necessary medical treatment, and informed consent was obtained from all patients involved in the study. Single cell RNA-seq (scRNA-seq) data processing The ACC tissue was dissociated into a single-cell suspension, and libraries were constructed using the 10x Genomics Chromium Single Cell 3’ Library Kit and Controller. Sequencing was performed on the Illumina NovaSeq 6000 platform. The resulting FASTQ files were processed with the CellRanger software, aligning them to the human genome to generate the gene expression matrix. Quality control was conducted in the R environment using the Seurat package with the following criteria: 1) genes expressed in at least three cells; 2) cells containing between 300 and 3000 features; 3) cells with mitochondrial gene read percentages below 10%; 4) cells with total counts below 10,000 (Supplementary Fig. 1A-D). Batch effects and technical noise between different cells were corrected using the SCTransform function in Seurat. The DoubletFinder tool was then applied to remove doublets from cells based on the top 20 principal components from principal component analysis (PCA), with the expected doublet rate set as per the Chromium Single-Cell 3’ v2 reagents kit user guide (10X Genomics). A set of 3000 Highly Variable Genes (HVGs) was selected for PCA analysis, and batch effects between samples were further adjusted using the harmony tool to correct PC values (Supplementary Fig. 1E-F). For cell clustering analysis, the K-Nearest Neighbors (KNN) clustering algorithm was employed, and the Wilcoxon rank-sum test was used to identify gene expression differences between clusters. Genes with corrected p-values below 0.05 and log2 fold changes of 0.25 or greater were identified as significant marker genes for each cluster. These marker genes were subsequently uploaded to the CellMarker online database for cell type identification. Cell developmental trajectories were inferred using the Monocle2 package based on 3,000 highly variable genes. Cell cycle scoring was performed using the CellCycleScoring function in the Seurat package. Transcription factor activity analysis was conducted with the Single-Cell rEgulatory Network Inference and Clustering (SCENIC) package. H&E staining Tissue samples were fixed in 10% neutral buffered formalin for 12–24 h. Dehydration was carried out by immersing the samples in a graded series of ethanol (70%, 80%, 90%, 95%, and 100%), each for 5 min. The samples were then treated with xylene twice for 5 min each. After paraffin embedding, 5 μm sections were cut. Sections were deparaffinized by immersing them in xylene three times for 5 min each. They were then rehydrated in a graded series of ethanol (100%, 95%, 85%, and 75%), each for 2 min, followed by rinsing in distilled water for 2 min. Hematoxylin staining was performed for 5 min, followed by rinsing under running water for 1 min. Sections were differentiated with 0.1% acid alcohol for a few seconds and then rinsed under running water. Treatment with 1% ammonia water for 30 s was followed by a 1-minute rinse under running water. Staining with 1% eosin was done for 30 s, followed by rinsing under running water. Sections were dehydrated in a graded series of ethanol (75%, 85%, 95%, and 100%), each for 2 min. The samples were then immersed in xylene twice, each for 5 min. Finally, the sections were mounted with neutral balsam for microscopic examination. Immunofluorescence of tissues Freshly harvested tissues were fixed in 10% paraformaldehyde for more than 24 h before being embedded in paraffin. The pathological sections underwent deparaffinization, followed by antigen retrieval with Tris-EDTA solution (Servicebio). For immunofluorescence staining, the sections were blocked with 20% BSA at room temperature for 30 min, then incubated with primary antibodies in PBS overnight at 4℃. After washing, they were incubated with fluorescently labeled secondary antibodies. The antibodies used included pan-CK (Proteintech, 26411-1-AP), Vimentin (Proteintech, 22031-1-AP), melanoma cell adhesion molecule (MCAM) (Proteintech, 17564-1-AP), anti-human-CD31 (Proteintech, 11265-1-AP), anti-mouse-CD31 (Proteintech, 80530-1-RR). Images were acquired using the Pannoramic MIDI II-3Dhistech, and data analysis was performed with CaseViewer and ImageJ2 Software. Purification of primary fibroblasts After excision, tumor tissues were trimmed into approximately 2 mm pieces and soaked in an antibiotic solution containing penicillin, streptomycin, and gentamicin for 2 h. The tissue fragments were then placed in six-well plates with RPMI 1640 medium (Gibco) containing 20% fetal bovine serum (FBS) (Cytiva) and antibiotics (penicillin-streptomycin-gentamicin), ensuring that the tissue pieces were not completely submerged. The cultures were maintained at 37 °C with 5% CO₂ for 7 days. Once 10–20 layers of cells were observed growing around the tissue pieces, the tissue fragments were removed. When the cells covered approximately 50% of the well surface, they were quickly digested with 0.25% trypsin (NCM) at 37℃ for about 1 min. The detached cells were collected and re-seeded into new six-well plates. This process was repeated when cells reached 50–60% confluency, and trypsin digestion was conducted again for about 1 min at 37℃. The above steps were repeated for 5–6 cycles until only spindle-shaped cells remained in the wells. These cells were verified as purified fibroblasts by immunofluorescence staining. The trypsin-purified fibroblasts were then diluted in complete medium and seeded into 96-well plates, ensuring only one cell per well. Cells were stimulated with 10 ng/µL of FGF-acidic (Peprotech, 100–17 A) to promote growth. Once the cells reached 50–60% confluency, they were passaged and subjected to immunofluorescence identification. Fibroblasts expressing specific marker proteins were confirmed and retained for subsequent experiments. Cell culture Human umbilical vein endothelial cells (HUVEC) and the salivary gland adenoid cystic carcinoma cell line 83 (SACC83) were obtained from the cell bank of the Hunan Key Laboratory of Otorhinolaryngology Major Diseases and were verified by short tandem repeat (STR) profiling. HUVECs and primary fibroblasts were cultured in RPMI 1640 medium (Gibco) containing 10% FBS (Cytiva) and a penicillin-streptomycin-gentamicin antibiotic mixture (NCM) at 37℃ with 5% CO₂. SACC83 cells were cultured in DMEM medium (Gibco) supplemented with 10% FBS (Ctiva) and penicillin-streptomycin-gentamicin (NCM) under the same conditions. Plasmid amplification The plasmid pLenti-U6-shMEF2C-CMV-GFP-2 A-Puro was purchased from PULLEN Biotechnology (Guangzhou, China). Competent TOP10 E. coli cells were transformed with the plasmid by incubating on ice for 20 min, followed by heat shock at 42℃ for 45 s, then immediately placed on ice for 2–3 min. The bacteria were then incubated with 500 µL LB medium (NCM) at 37℃ for 1 h to recover. After recovery, 100 µL of the bacterial suspension was plated onto LB agar and incubated at 38℃ for 12 h. A single colony was picked and expanded in LB medium containing ampicillin on a shaker at 37℃ for 12 h. Bacterial cells were harvested by centrifugation at 10,000 g for 1 min, and plasmid DNA was extracted using the GoldHi EndoFree Plasmid Midi Kit (CWBIO) following the manufacturer’s instructions. The plasmid was eluted and stored at −20℃ for long-term use. Virus packaging and lentiviral infection 293 T cells were cultured to 80% confluence and then the medium was replaced with DMEM base medium. Lipofectamine 3000 (Invitrogen) was mixed with Opti-MEM (Gibco) to form solution A, while the target plasmid, packaging plasmid, and P3000 reagent (Invitrogen) were mixed with Opti-MEM to form solution B. After both solutions were incubated for 5 min, they were combined and incubated for 20 min. The mixture was then added to 293 T cells. After 8 h of transfection, the medium was replaced with complete DMEM (Gibco). After 24 h of transfection, the viral supernatant was collected and mixed with RPMI 1640 (Gibco) complete medium at a 1:1 ratio. This mixture was added to primary fibroblasts at 40% confluency for 48 h of infection. Puromycin selection was applied for one week to ensure stable expression, and the transfection efficiency was verified afterward. Colony formation assay Cells in the logarithmic growth phase were digested with trypsin and resuspended in complete RPMI 1640 (Gibco) medium containing 10% FBS (Cytiva) to create a cell suspension. In each experimental group, 500 cells per well were seeded into a 6-well plate. The cells were cultured for 14 days or until the majority of individual colonies contained more than 50 cells, with medium changes and cell observations every 3 days. Colonies were photographed under a microscope. After washing, 4% paraformaldehyde was added to each well for 30 min to fix the cells. Then, 1 mL of crystal violet staining solution (Solarbio) was added to each well to stain the cells for 20 min. After washing with PBS, the plates were air-dried and photographed. Transwell assay Cells in the logarithmic growth phase were digested with trypsin (NCM) and resuspended to a concentration of approximately 5 × 10⁵ cells/mL. Then, 200 µL of the cell suspension was added to the upper chamber of the transwell insert (Corning). The lower chamber was filled with 800 µL of RPMI 1640 (Gibco) complete medium containing 10% FBS (Cytiva), serum-free medium, or conditioned medium. The cells were cultured in a 37℃ incubator for 24 h. Non-invasive cells on the upper surface of the membrane were removed with a cotton swab. The membrane was fixed at room temperature with 4% paraformaldehyde for 30 min, stained at room temperature with crystal violet for 30 min, and then air-dried. The stained cells were photographed and counted. Cell counting kit 8 (CCK-8) assay Cells were seeded into a 96-well plate and starved in serum-free RPMI 1640 (Gibco) medium for 24 h. After removing the medium, cells were treated with different conditioned media for an additional 24 h. The medium was then aspirated, and the wells were washed three times with PBS. Next, 90 µL of serum-free RPMI 1640 medium (Gibco) was added to each well, followed by the addition of 10 µL of CCK-8 solution (Solarbio). The plate was incubated at 37 °C with 5% CO₂ for 2 h. Absorbance was measured at 450 nm using a microplate reader to determine the optical density (OD) of each well. Angiogenesis assay Low-growth factor Matrix-Gel™ (Beyotime) was mixed with RPMI 1640 (Gibco) medium in a 1:1 ratio and then plated in a 96-well plate at 30 µL per well. The plate was incubated at 37℃ for 30 min to allow the gel to solidify. HUVEC cells were resuspended in different conditioned media and seeded onto the matrigel-coated 96-well plate at 50 µL per well, with a density of 10,000 cells per well. The plate was then incubated at 37℃ with 5% CO₂. Tube formation was observed under a microscope at 2 h, 6 h, and 12 h, and images were captured at each time point. Leukocyte transendothelial migration assay Resuspend HUVEC cells in RPMI 1640 medium (Gibco) containing 10% FBS (Cytiva), then seed them in the upper chamber of a transwell insert with a pore size of 3.5 μm. Add serum-free medium to the lower chamber and continue to culture for 24 h to allow HUVEC cells to cover the upper surface of the membrane. Remove the serum-containing medium and culture the cells in serum-free RPMI 1640 medium (Gibco) for 6 h. Add conditioned medium to the upper chamber and continue culturing for another 24 h before removing it. Isolate peripheral blood mononuclear cells (PBMCs) from a healthy donor using FICOLL PAQUE PREMIUM (Cytiva). Resuspend human PBMCs in serum-free RPMI 1640 medium (Gibco), add 1 million PBMCs in 200 µL to the upper chamber, and add medium containing 10 ng/mL human stromal cell-derived factor 1 (SDF-1) (novoprotein, C121) to the lower chamber. After an additional 24 h of incubation, count the cells in the lower chamber. Immunofluorescence staining of cells Discard the supernatant from cell cultures and wash the samples with PBS three times. Fix the cells in 4% paraformaldehyde at room temperature for 20 min. Remove the paraformaldehyde and wash the samples with PBS three times. Block non-specific binding by incubating with 2.5% BSA (NCM) at room temperature for 1 h. After removing the blocking solution, wash with PBST three times. Incubate the samples with primary antibody, diluted in blocking solution, overnight at 4℃. Discard the primary antibody solution and wash with PBST three times. Incubate with secondary antibody, diluted in blocking solution, at room temperature in the dark for 1 h. Remove the secondary antibody solution and wash with PBST three times. Counterstain with DAPI (Beyotime) at room temperature for 5 min. After staining, remove the solution and wash with PBST three times. Mount the samples using a fluorescence quenching mounting medium and examine under a microscope. The antibodies used included pan-CK (Proteintech, 26411-1-AP), Vimentin (Proteintech, 22031-1-AP), MCAM (Proteintech, 17564-1-AP), and goat anti-rabbit antibodies conjugated with APC (Proteintech). Western-blot The treated cells were harvested and lysed using RIPA buffer (Beyotime), followed by incubation on a rocker at 4℃ for 15 min. Protein concentrations in the lysates were determined using a bicinchoninic acid (BCA) protein assay kit (Beyotime) and equalized across all samples. Proteins were resolved by 10% SDS-PAGE (Epizyme) and transferred onto PVDF membranes (Millipore). The membranes were incubated with primary antibodies against myocyte enhancer factor 2 C (MEF2C) (Abcam, ab211493), followed by incubation with HRP-conjugated goat anti-rabbit secondary antibodies (Proteintech, RGAR001). Immunoreactive bands were detected using enhanced chemiluminescence (ECL) reagent (Beyotime, P0018S). To confirm equal protein loading, the membranes were reprobed with antibodies targeting GAPDH (Proteintech, 60004-1). Q-PCR Cells were harvested into 1.5 mL microcentrifuge tubes, washed with PBS, and then incubated with 1 mL of Trizol (Invitrogen) at room temperature for 5 min. Subsequently, 200 µL of chloroform was added to each tube, followed by vigorous shaking for 30 s until the solution became cloudy. The tubes were left at room temperature for another 5 min. The clear upper phase was carefully transferred to new 1.5 mL tubes, yielding approximately 400–500 µL per tube. An equal volume of isopropanol was added, mixed well, and incubated at room temperature for 10 min. Samples were centrifuged at 12,000 rpm for 10 min at 4℃, producing a white pellet at the bottom of the tube. This pellet was washed twice with 75% ethanol, air-dried on ice, and resuspended in 10 µL of RNase-free water. RNA concentration and purity were assessed using a spectrophotometer by measuring absorbance at 260 nm/280 nm. The SweScript RT II First Strand cDNA Synthesis Kit (Servicebio) was used to remove genomic DNA and reverse transcribe the RNA into cDNA. qPCR was conducted using Fast SYBR Green qPCR Master Mix (Servicebio), with the following thermal cycling conditions: initial denaturation at 95℃ for 30 s, followed by 40 cycles of 95℃ for 10 s, and 60℃ for 30 s for annealing/extension. Primers (listed in Supplementary Table 1) were synthesized by Sangon Biotech (Shanghai, China). Enzyme-linked immunosorbent assay (ELISA) assay ELISA kits were purchased from CUSABIO (Wuhan, China). Cell culture supernatants were centrifuged to remove debris and either assayed immediately or stored at − 20℃ until use. All reagents were equilibrated to room temperature for 30 min and working solutions were prepared according to the manufacturer’s instructions. Briefly, 100 µL of standards or samples were added to the pre-coated 96-well plate and incubated at 37℃ for 2 h. After removing the liquid without washing, 100 µL of diluted biotin-conjugated antibody was added to each well and incubated at 37℃ for 1 h. Wells were then aspirated and washed three times with 200 µL of wash buffer. Subsequently, 100 µL of diluted HRP-avidin was added and incubated at 37℃ for 1 h, followed by five washes. Ninety microliters of TMB substrate was added to each well and incubated at 37℃ for 15–30 min in the dark. The reaction was stopped by adding 50 µL of stop solution to each well, and the absorbance at 450 nm was measured using a microplate reader. Concentrations of target proteins were calculated from the standard curve. Chromatin immunoprecipitation (ChIP) assay The 3000 bp upstream sequence of the transcription start site of the target gene was obtained from the National Center for Biotechnology Information (NCBI) database (https://www.ncbi.nlm.nih.gov/) as the potential promoter region. The JASPAR database (https://jaspar.elixir.no/) was used to predict potential MEF2C binding sites in the upstream region of the target gene, selecting the highest-scoring sites for further validation. ChIP assays were performed using the ChIP Assay Kit (Beyotime). Cells in 10 cm culture dishes were cross-linked with 1% formaldehyde in culture medium at 37℃ for 10 min. Cells were scraped, lysed in SDS Lysis Buffer on ice for 10 min, and sonicated to shear DNA into fragments of 200–1000 bp. Samples were centrifuged at 12,000–14,000 g for 5 min, and the supernatant was collected. The samples were diluted with ChIP Dilution Buffer containing 1 mM PMSF. A 20 µL aliquot was taken as Input for later analysis. The remaining sample was incubated with 70 µL of Protein A+G Agarose/Salmon Sperm DNA at 4℃ with rotation for 30 min. After centrifugation at 1000 g for 1 min at 4℃, the supernatant was retained. MEF2C antibody (1 µg) was added to the sample, with an isotype IgG antibody used as a negative control. The samples were then incubated with 60 µL of Protein A+G Agarose/Salmon Sperm DNA at 4℃ with gentle rotation for 60 min to precipitate the protein-DNA complexes. After centrifugation at 1000 g for 1 min at 4℃, the liquid was carefully removed. The pellet was washed sequentially according to the kit instructions. 5 M NaCl was added, and the samples were mixed and heated at 65℃ for 4 h to reverse the cross-links between proteins and genomic DNA. PCR amplification was then performed using PCR Master Mix (Beyotime). Primers (listed in Supplementary Table 2) were synthesized by Sangon Biotech (Shanghai, China). According to the manufacturer’s protocol, 2X PCR Master Mix, primers, 5 µL of the sample, and distilled water were combined to a total volume of 50 µL. The PCR parameters were as follows: initial denaturation at 94℃ for 3 min; denaturation at 94℃ for 30 s; annealing at 55℃ for 30 s; extension at 72℃ for 1 min; final extension at 72℃ for 10 min; for a total of 30 cycles. The amplified products were electrophoresed on agarose gels containing ethidium bromide and imaged under 345 nm UV light. Quantitative analysis was conducted by qPCR, and the relative amount of each gene in the control and immunoprecipitated samples was expressed as a percentage of the input DNA. The calculation was performed according to the formula: %Input = 2^(CtInput − CtIP) × dilution factor × 100%. Animal experiments The animal experiments were approved by the Animal Ethics Committee of Central South University (Approval No: CSU-2024-0145). SACC83 cells in the logarithmic growth phase were digested, centrifuged, and resuspended in PBS at a concentration of 2 × 10⁷ cells/mL. The cells were then mixed with logarithmic-phase wild-type primary fibroblasts or MEF2C knockdown fibroblasts at a 4:1 ratio. A 100 µL suspension was injected into the right axilla of 6-week-old BALB/c-nu nude mice. The control group received only tumor cells. Tumor length and width were measured on days 7, 10, and 14, and mice were euthanized on day 14 for tumor tissue collection and fixation. Measurement of weight and volume was performed using the micropipette drainage method. Results A high proportion of rapidly proliferating myofibroblasts in solid-type ACC We performed scRNA-seq on tissues from eight ACC patients who underwent surgical resection. These included three solid-type, three cribriform-type, and two tubular-type ACC cases (Supplementary File 3). Dimensionality reduction and clustering of the data identified fibroblast clusters expressing high levels of actin alpha 2 (ACTA2) and collagen type I alpha 1 chain (COL1A1) (Supplementary Fig. 1G). In solid-type ACC, fibroblasts accounted for over 50% of all cells, whereas in cribriform and tubular-type ACC, the proportion of fibroblasts was below 30% (Supplementary Fig. 1H). Additionally, solid-type ACC exhibited a higher proportion of endothelial cells (Supplementary Fig. 1H). Sub-clustering of fibroblasts (Fig. 1A) revealed seven distinct gene expression patterns (Fig. 1B), including two inflammatory fibroblast subtypes (C-X-C motif chemokine ligand (CXCL) 1+ iCAFs and complement component 3 (C3)+ iCAFs), characterized by the expression of inflammatory cytokines interleukin (IL) 6, IL11, and CXCL chemokines. There were two myofibroblast subtypes (transgelin (TAGLN)+ myCAFs and ACTA2+ myCAFs), marked by high expression of TAGLN and ACTA2. However, since the two subclusters positive for TAGLN and ACTA2 were located within the same cluster on the UMAP plot without a clear boundary, their separation likely lacks distinct biological significance and may result from technical noise. Therefore, these two subclusters were merged, and their shared marker genes were used to define them as MCAM+ myCAFs. Three fibroblast subtypes predominantly expressed matrix components like COL1A1 (CXCL14+ fibroblasts, asporin (ASPN)+ fibroblasts, and COL4A1 fibroblasts). In solid-type ACC, myCAFs comprised more than 50% of the total fibroblast population, compared to less than 30% in other ACC subtypes (Fig. 1C). Trajectory analysis revealed myCAFs were enriched at the differentiation endpoints, suggesting they may represent a specialized fibroblast subtype (Fig. 1D). Notably, the two myCAFs subtypes exhibited higher G2/M cell cycle scores, indicating increased proliferative activity (Fig. 1E). Single-cell transcriptomic landscape of fibroblasts in ACC. (A) A scatter plot shows the distribution of fibroblast subpopulations within ACC tissue after UMAP dimensionality reduction. (B) A bubble plot displays the expression levels of characteristic genes in different fibroblast subpopulations in ACC. The size of the bubbles represents the proportion of positive cells, and the color indicates the relative expression levels. (C) A stacked bar chart illustrates the proportions of fibroblast subpopulations in ACC with different pathological subtypes. (D) A scatter plot depicts the fibroblast differentiation trajectory inferred by Monocle2, with pseudotime values closer to 1 indicating proximity to the differentiation endpoint. (E) Violin plots compare the average G2/M cell cycle scores of fibroblast subpopulations inferred by Seurat Frequent interactions between endothelial cells and MCAM+ MyCAFs enhance angiogenic potential in solid-type ACC We compared the expression of angiogenesis-related factors and membrane proteins across different fibroblast subtypes. MyCAFs exhibited higher expression of angiogenic factors, including platelet-derived growth factor subunit A (PDGFA), placental growth factor (PGF), angiopoietin-1 (ANGPT1), and angiopoietin-2 (ANGPT2), but not vascular endothelial growth factor (VEGF) (Fig. 2A). The gene MCAM emerged as a specific marker for both myCAFs subtypes. In fibroblast differentiation analysis, the expression of angiogenic factors increased, except for VEGF, which decreased as fibroblasts differentiated into MCAM+ myCAFs (Figs. 1D and 2B). Genes involved in matrix formation and remodeling, such as COL1A1 and matrix metalloproteinase (MMP) 3, were downregulated. Endothelial cells in solid-type ACC exhibited high expression of angiogenesis-related receptors, including fms-related receptor tyrosine kinase (FLT) 1, FLT4, kinase insert domain receptor (KDR), PDGFR, and tyrosine kinase with immunoglobulin-like and EGF-like domains (TIE), in contrast to low expression in cribriform and tubular-type ACC (Fig. 2C), indicating a stronger angiogenic response in solid-type ACC. Additionally, endothelial cells in solid-type ACC expressed higher levels of B-cell lymphoma 2 (BCL2), notch receptor 1 (NOTCH1), and ephrin-A1 (EFNA1), while adhesion molecules expression was reduced (Fig. 2D), suggesting enhanced angiogenesis and impaired immune function. Enrichment analysis revealed similar results, with solid-type ACC endothelial cells primarily activating angiogenesis-related pathways, while adaptive immune functions were diminished (Fig. 2E). Expression profile of angiogenic factors in fibroblast subpopulations within ACC. (A) Bubble plot showing the expression levels of key angiogenic factors and related membrane proteins across different fibroblast subpopulations in ACC. Bubble size represents the percentage of cells expressing the gene, while color indicates relative expression levels. (B) Pseudotime analysis illustrating the progression of fibroblasts towards differentiation into MCAM+ myCAFs, with key angiogenic factors marked along the trajectory. (C) Expression levels of angiogenic factors in fibroblast subpopulations and their corresponding ligands in endothelial cells from different pathological types of ACC, with color indicating relative expression levels. (D) Expression levels of genes involved in angiogenic proliferation, differentiation, and adhesion molecules in endothelial cells from different pathological types of ACC, with color indicating relative expression levels. (E) Bubble plot showing the enrichment analysis of genes activated or suppressed in MCAM+ myCAFs, with bubble size representing the number of enriched genes and color indicating the P-value Angiogenesis primarily occurs in the stroma of solid-type ACC, with MCAM+CAFs as the major source of angiogenic factors We performed immunofluorescence staining on solid and non-solid ACC tissues to assess the localization and abundance of MCAM+ myCAFs. The stroma in both solid and non-solid ACC was mainly composed of Vimentin-positive fibroblasts, but only in solid-type ACC was MCAM expressed in the stroma (Fig. 3A). In solid-type ACC, the stroma contained numerous CD31-positive microvessels, absent in non-solid ACC. No microvessels were observed in the epithelial regions (pan-CK+) of either ACC type. Interestingly, MCAM was preferentially located around CD31-positive microvessels (Fig. 3A, panels 1). In addition, we compared the proportion of MCAM expression area in the vimentin expression area, and the results showed that this proportion was significantly higher in solid-type ACC than in non-solid type ACC (Fig. 3B). ScRNA-seq data revealed that fibroblasts were the primary source of angiogenic factor mRNA in solid-type ACC, contributing around 50% (Fig. 3C). In contrast, epithelial cells (tumor cells) were the main source of angiogenic factors in non-solid ACC. Fibroblasts had higher angiogenesis scores than tumor cells in both solid and non-solid ACC (Fig. 3D), indicating that stromal fibroblasts, especially in solid-type ACC, are the main contributors to neovascularization. Immunofluorescence staining in additional samples confirmed that microvessel density was significantly higher in the stroma of solid-type ACC compared to non-solid ACC (Fig. 3E-F), while both ACC types showed low microvessel density in the epithelial regions (Fig. 3E-F). Microvascular distribution and sources of angiogenic factors in different pathological types of ACC. (A) Immunofluorescence staining shows the expression distribution of epithelial, endothelial, and MCAM+ CAF marker proteins in solid and non-solid ACC. (B) Pie charts illustrate the proportion of angiogenic factor gene reads expressed by different major cell types in solid and non-solid ACC, as a percentage of the total detected angiogenic factor gene reads. (C) Box plots compare the mean angiogenic factor expression scores among different major cell types in solid and non-solid ACC. (D) Immunofluorescence staining shows the distribution of CD31 expression in the stromal and parenchymal regions of solid and non-solid ACC, with the tumor parenchyma outlined by dashed lines. (E) Bar graph comparing microvascular density in the stromal and parenchymal regions of solid and non-solid ACC, significance: ****P < 0.0001, nsP≥0.05 MCAM+ MyCAFs from solid ACC significantly influence endothelial cell tubule formation and immune function Fibroblasts were isolated and purified from three non-solid (nS) and two solid (S) ACC tissues. Immunofluorescence staining showed that the fibroblasts were pan-CK-negative and Vimentin-positive, with nS-CAFs being MCAM-negative and S-CAFs MCAM-positive (Supplementary Fig. 2), indicating that the purified S-CAFs represent a population of MCAM+ myCAFs. A comparison of the expression levels of angiogenic factors between nS-CAFs and S-CAFs showed that S-CAFs expressed significantly higher levels of PDGFA, PGF, ANGPT1, and ANGPT2, although VEGFA expression was slightly lower in S-CAFs than in nS-CAFs, but this difference was not statistically significant (Fig. 4A; Supplementary Fig. 3A-E). Clonogenic assays revealed that S-CAFs had significantly higher proliferative capacity compared to nS-CAFs, consistent with the scRNA-seq analysis (Fig. 4B-D). Conditioned media from S-CAFs induced greater migration of HUVEC cells than that from nS-CAFs (Fig. 4E). When HUVEC cells were cultured in conditioned media from S-CAFs or nS-CAFs for 24 h, both media promoted HUVEC proliferation, but no significant difference was observed between them (Fig. 4F-G). However, S-CAF-conditioned media induced significant tubule formation in HUVECs within six hours, whereas nS-CAF-conditioned media did not (Fig. 4H). Additionally, both S-CAFs and nS-CAFs upregulated the expression of proliferation and differentiation markers (marker of proliferation Ki-67 (MKI67) and NOTCH1) in HUVECs, with S-CAFs exhibiting stronger effects (Fig. 4I). In terms of adhesion molecule expression, S-CAFs and nS-CAFs downregulated selectin L (SELL), vascular cell adhesion molecule 1 (VCAM1), and intercellular adhesion molecule 1 (ICAM1) expression in HUVECs, with S-CAFs exerting a stronger effect on VCAM1 downregulation (Fig. 4I). In leukocyte migration assays, both S-CAFs and nS-CAFs reduced leukocyte migration across HUVEC monolayers, with no significant difference between the two (Fig. 4J). Comparison of the pro-angiogenic effects of MCAM+ CAFs from solid ACC and MCAM− CAFs from non-solid ACC. (A) Bar graph comparing the mRNA expression levels of angiogenic factors in CAFs from different origins. Statistical analysis compares the overall mean values of two solid-derived MCAM+ CAFs with the overall mean values of three non-solid-derived MCAM− CAFs. nS represents non-solid and S represents solid, the same applies throughout. Significance: ****P < 0.0001, **P < 0.01, nsP≥0.05. (B) Colony Formation assay results for CAFs from different origins. (C) Comparison of the number of colons from CAFs of different origins, significance: ***P < 0.001. (D) Comparison of the number of cells per colony from CAFs of different origins, significance: ****P < 0.0001, ***P < 0.001, nsP≥0.05. (E) The bar chart shows the results of the CCK-8 assay performed on HUVEC cells cultured with conditioned media derived from CAFs of different origins, significance: ***P < 0.001, *P < 0.05, nsP≥0.05. (F) Transwell assay showing the migration of HUVECs induced by conditioned media from CAFs of different origins. (G) Comparison of the number of HUVECs migrating to the lower chamber of the transwell apparatus, significance: ***P < 0.001, *P < 0.05, nsP≥0.05. (H) Results of HUVEC tubule formation induced by conditioned media from CAFs of different origins. (I) Comparison of mRNA expression levels of functional molecules in HUVECs induced by conditioned media from CAFs of different origins, significance: ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05, nsP≥0.05. (J) Comparison of the number of PBMCs migrating across HUVEC monolayers to the lower chamber of the transwell apparatus after treatment with conditioned media from CAFs of different origins, significance: ****P < 0.0001, nsP≥0.05 MEF2C as a key transcription factor regulating angiogenic factors in MCAM+ MyCAFs To identify potential transcription factors regulating angiogenic factors in MCAM+ myCAFs, we first performed SCENIC analysis on the scRNA-seq data. For the following results, we chose MEF2C for further exploring (Fig. 5A-B): (1) We analyzed the transcription factor activity of MCAM+ myCAFs based on single-cell sequencing data and found that MEF2C exhibited significantly higher activity in MCAM+ myCAFs compared with other fibroblast subpopulations; (2) Unlike other transcription factors that were highly expressed in MCAM+ myCAFs (such as FOXC2), MEF2C was predicted in motif analysis to have regulatory relationships with multiple angiogenic factors—including PDGF and ANGPT—but not VEGFA. In contrast, the other upregulated transcription factors were not predicted to regulate angiogenesis-related factors. Based on these predictions, we identified PDGFA, PDGFB, ANGPT1, and ANGPT2 as candidate targets of MEF2C and designed primers to perform ChIP-PCR (Fig. 5D-E). ChIP-PCR results confirmed the binding of MEF2C to the promoter regions of PDGFA, PDGFB, ANGPT1, and ANGPT2, but not VEGFA (Fig. 5F; Supplementary Fig. 4A-D). Upstream regulatory mechanisms of angiogenic factor transcription in MCAM+ myCAFs. (A) Heatmap showing the relative expression levels of transcription factors and their regulatory units in different fibroblast subpopulations. (B) Target genes of the transcription factor MEF2C in MCAM+ myCAFs: “highConf” indicates whether the target is of high confidence; “nMotifs” represents the number of binding sites upstream of the target genes; “NES” indicates the enrichment score. (C) Binding pattern of MEF2C with the upstream sequences of target genes. (D) MEF2C protein levels in different control groups in ChIP experiments. (E) JASPAR-predicted binding sites of MEF2C upstream of angiogenic factor genes. (F) Electrophoresis results showing the PCR-amplified nucleic acid bands of upstream binding site sequences of angiogenic factors from different ChIP control groups MEF2C knockdown inhibits the pro-angiogenic capability of MCAM+ MyCAFs In Vitro and In Vivo Immunofluorescence staining revealed that MEF2C was predominantly localized in the nuclei of MCAM+ myCAFs (Fig. 6A), consistent with its role as a transcription factor. We then established a stable knockdown of MEF2C in MCAM+ myCAFs using shRNA (Fig. 6B). Tubulogenesis assays showed that the pro-tubulogenesis effect of shMEF2C-transfected MCAM+ myCAFs on HUVEC cells was significantly reduced compared to shNC controls (Fig. 6C). MEF2C knockdown also significantly downregulated the mRNA and protein expression of VEGFA, PDGFA, PDGFB, ANGPT1, and ANGPT2 expression (Fig. 6D; Supplementary Fig. 5A-E). Notably, MEF2C knockdown did not alter the proliferative capacity of MCAM+ myCAFs (Fig. 6E-F). We selected S-CAFs with better MEF2C knockdown efficiency (S-CAFs-1) and co-implanted them with SACC83 cells subcutaneously in nude mice. After 14 days, the tumor volume in the shMEF2C group was significantly smaller than in the shNC group but slightly larger than tumors from SACC83-only injections (Fig. 6G-I). Additionally, microvessel density in the tumors from the shMEF2C group was significantly reduced compared to the shNC group, but still slightly higher than that in tumors from the SACC83-only group (Fig. 6J-K). The impact of MEF2C knockdown on the pro-angiogenic capacity of MCAM+ myCAFs. (A) Immunofluorescence staining shows the localization of MEF2C expression in MCAM+ myCAFs. (B) Western blot showing MEF2C protein levels in primary MCAM+ myCAFs before and after MEF2C knockdown. (C) Tubule formation assay of HUVEC cells induced by conditioned medium from primary MCAM+ myCAFs before and after MEF2C knockdown. (D) Expression of pro-angiogenic factors in primary MCAM+ myCAFs before and after MEF2C knockdown. (E) Colony formation assay of primary MCAM+ myCAFs before and after MEF2C knockdown. (F) Comparison of the number of colonies formed. nsP≥0.05. (G) Tumor formation of mixed MCAM+ myCAFs and SACC83 cells in subcutaneous xenografts in nude mice before and after MEF2C knockdown. (H) Comparison of tumor weight 14 days post-implantation. significance: *P < 0.05, nsP≥0.05. (I) Comparison of tumor volume 14 days post-implantation. significance: *P < 0.05, nsP≥0.05. (J) H&E staining (upper) and immunofluorescence staining (lower) of xenografts, with blood vessels marked by CD31. (K) Comparison of microvessel density within the xenografts. significance: ****P < 0.0001, nsP≥0.05 Discussion Fibroblasts play a pivotal role in angiogenesis. Early studies demonstrated that co-culturing fibroblasts with endothelial cells can simulate the in vivo angiogenic microenvironment. For instance, cell contact between HUVECs and human fibroblasts (hFBs) facilitates the formation of capillary-like networks with luminal structures in vitro [18]. Swiss 3T3 fibroblasts were shown to induce capillary-like structures in endothelial cells in co-culture systems [19]. Fibroblasts contribute to angiogenesis through multiple mechanisms, including the secretion of growth factors, extracellular matrix remodeling, and interactions with endothelial cells. In breast cancer, the angiogenic potential of CAFs is regulated by DNMT1 through the upregulation of VEGF-A, IL-8, and their upstream effectors, mTOR and HIF-1α [20]. Besides growth factors, certain genes expressed by fibroblasts, such as collagen I and procollagen C-proteinase enhancer 1, are crucial for luminal formation, a key step in angiogenesis [21]. Fibroblasts also regulate angiogenesis by directly interacting with endothelial cells through membrane proteins. For example, fibroblasts express specific adhesion molecules such as VE-cadherin (cadherin-5), which promotes adhesion to endothelial cells, stabilizing their tubular structures and playing a key role in angiogenesis [22]. These findings highlight the multifaceted role of fibroblasts in angiogenesis, making CAFs increasingly recognized as key players in tumor-associated neovascularization. CAFs promote angiogenesis in prostate, colon, and breast cancers by secreting classical factors such as VEGF [23–25]. Additionally, other factors, including pro-angiogenic molecules [24], exosomes, noncoding RNAs [26–28], and matrix proteins [29] have been implicated in CAF-driven tumor angiogenesis. In ACC, CAFs have been reported to be the predominant cell type in the tumor microenvironment [17]. However, the function of this large population of CAFs, including their pro-angiogenic potential, remains unexplored. Solid-type ACC, characterized by dense sheets of basaloid cells and a lack of cribriform or tubular structures, has the poorest prognosis and is the most aggressive subtype, especially when the Ki-67 index exceeds 30%, known as HGT [3, 4, 30, 31]. In our study, we observed a high density of CAFs and microvessels in the stroma of solid-type ACC. Importantly, analysis of the sources of pro-angiogenic factors in solid-type ACC revealed that tumor cells contributed minimally, with CAFs accounting for over 50% of the pro-angiogenic factors. This finding suggests that although solid-type ACC requires extensive neovascularization to sustain its rapid growth, tumor cells alone are insufficient to provide the necessary angiogenic factors, and CAFs assume this responsibility. Further analysis revealed that the majority of CAFs in solid-type ACC are MCAM+ myCAFs, which significantly overexpress angiogenic factors such as PDGFA, PGF, ANGPT1, and ANGPT2, and possess stronger pro-angiogenic capabilities compared to MCAM- fibroblasts from non-solid-type ACC. These results underscore the critical role of MCAM+ myCAFs in angiogenesis and tumor progression in solid-type ACC, as demonstrated by both in vitro and in vivo experiments. We found that MEF2C is highly upregulated in MCAM+ myCAFs and identified its regulatory role in angiogenic factor expression. Most research on Myocyte Enhancer Factor 2 C (MEF2C) has focused on neurological diseases, where it is implicated in embryonic brain development, neuron formation and differentiation, as well as axonal and dendritic growth and pruning [32]. MEF2C is involved in the development of disorders such as autism spectrum disorder (ASD), epilepsy, schizophrenia, and Alzheimer’s disease (AD) [33, 34]. In addition, MEF2C overexpression has been shown to suppress extracellular matrix synthesis by cardiac fibroblasts (CFs) and convert them into induced cardiomyocytes (iCMs), preventing ventricular remodeling [35, 36]. This highlights MEF2C’s critical role in fibroblast phenotype transformation. Single-cell sequencing studies of CAFs have also identified MEF2C upregulation in certain CAF subsets, although the significance of this remains unclear [37, 38]. Beyond fibroblasts, MEF2C has also been found in endothelial cells [39, 40], where it is induced by VEGF in a dose- and time-dependent manner and acts as a key mediator of VEGF-induced endothelial migration [41]. This suggests MEF2C’s pivotal role in angiogenesis. However, no study has yet elucidated how MEF2C regulates neovascularization or the function of MEF2C-expressing CAF subsets in angiogenesis. In our study, we confirmed that MEF2C binds to the promoter regions of PDGFA/B and ANGPT1/2, upregulating their transcription. Additionally, knockdown of MEF2C inhibited angiogenesis within the tumor in vivo, filling the knowledge gap regarding the role of MEF2C in CAFs. Interestingly, VEGF, the classical angiogenic factor, was not highly expressed in CAFs from solid-type ACC and was not regulated by MEF2C. In fact, factors such as PDGF, ANGPT1, and ANGPT2 have been shown to be as potent as VEGF in promoting angiogenesis [42–44]. This suggests that the key drivers of angiogenesis in different subtypes of the same tumor may vary, an important consideration for treatment and drug development. However, our study also has certain limitations. In the single-cell sequencing analysis of ACC cellular subpopulations, the number of patient samples for each pathological subtype was relatively small. This limitation may have exaggerated or obscured some differences in the proportions of specific cell subpopulations. To address this issue, we conducted expanded validation using clinical samples. In the future, we aim to perform sequencing analyses on a larger variety of pathological subtypes to uncover additional meaningful alterations in cellular subpopulation composition. In addition, this study did not include “normal fibroblasts” as controls in the cell or animal experiments, for the following reasons: (1) Due to the limited scope of our case collection, all samples were derived from minor salivary glands of the nasal cavity. The corresponding adjacent non-cancerous tissues consisted of nasal mucosa rather than glandular tissue, and the inherent differences in fibroblast identity between these tissues could distort experimental outcomes. (2) We also attempted to use so-called “normal fibroblast cell lines,” such as HSF (human skin fibroblasts). However, the substantial differences in tissue origin led us to abandon this approach. Moreover, these cell lines are often immortalized, and their genomic alterations may pose a significant risk of confounding or distorting the experimental results. (3) Finally, as our experiments were designed to compare solid-type versus non-solid-type adenoid cystic carcinoma (ACC), using fibroblasts from non-solid-type ACC as controls still allowed us to capture the characteristic alterations of fibroblasts associated with solid-type ACC. In future studies, fibroblasts derived from benign salivary gland tumors such as pleomorphic adenomas could be included as supplementary controls to further strengthen and refine the conclusions. In conclusion, our study identifies a predominant fibroblast population in solid-type ACC, namely MCAM+ myCAFs. These cells upregulate MEF2C expression, promoting the transcription of pro-angiogenic factors such as PDGFA/B and ANGPT1/2, thereby serving as the primary source of angiogenic factors in the tumor microenvironment of solid-type ACC. Future studies exploring the interaction between tumor cells and fibroblasts in solid-type ACC may provide further insights into the formation of MCAM+ myCAFs and the upstream regulation of MEF2C. Supplementary Information Supplementary Material 1. Supplementary Figure 1. Quality control and cell type annotation of single-cell data. (A)-(D) Detected number of genes (nFeature), reads (nCount), mitochondrial gene percentage (percent.mt), and number of erythrocyte genes (percent.HB) for each of the 8 samples. (E)-(F) PCA analysis of samples before and after harmony correction, with different colors indicating the distribution of the 8 samples. (G) Expression of marker genes for major cell types. (H) Composition of major cell types in different pathological types of ACC. Supplementary Figure 2. Expression of marker proteins in ACC tumor cell lines and primary fibroblasts. CAFs express vimentin but not CK; MCAM+ myCAFs derived from the solid-type ACC specifically express MCAM, whereas CAFs derived from the non-solid type do not express MCAM. Supplementary Figure 3. Expression of angiogenic factors in CAFs from different sources. (A)–(E) Bar graphs comparing the protein expression levels of angiogenic factors in the culture supernatants of CAFs from different origins. Statistical analysis compares the overall mean values of two solid-derived MCAM+ CAFs with the overall mean values of three non-solid-derived MCAM- CAFs. nS represents non-solid and S represents solid, the same applies throughout. Significance: ****P<0.0001, **P<0.01, nsP≥0.05. Supplementary Figure 4. Quantitative Analysis of ChIP Assays for MEF2C Binding to Promoter Regions of Angiogenic Factors. (A)-(D) Panels A-D present the quantitative analysis results of ChIP experiments on the promoter regions of MEF2C with PDGFA, PDGFB, ANGPT1, and ANGPT2, respectively. The data for VEGFA's two targets are not shown due to absence of signals in both cases. Significance:**P<0.01, *P<0.05, nsP≥0.05. Supplementary Figure 5. Pro-angiogenic factor expression in S-CAFs after MEF2C knockdown. (A)-(E) Bar graphs comparing the protein expression levels of pro-angiogenic factors in the culture supernatants of S-CAFs before and after MEF2C knockdown. Statistical analysis compares the overall mean values of the two cell lines before and after knockdown. Significance: ****P<0.0001, ***P<0.001, **P<0.01,*P<0.05. Supplementary Material 2. Supplementary Material 3. Supplementary Material 4. Supplementary Material 5. Supplementary Material 6. Supplementary Material 7. Supplementary Material 8. Acknowledgements We would like to thank Dr. Zhenhua Zhang of Sun Yat-sen University for his help with statistics and bioinformatics. The paper uses ChatGPT to polish the language. Author contributions Xiaotian Yuan, Hua Zhang, Yongzhen Mo, Weihong Jiang: conceived and designed the experiments; Xiaotian Yuan, Yunqing Liu, Benjian Zhang: performed the experiments; Xiaotian Yuan, Benjian Zhang, Lai Meng, Yan Fang, Zirong Chen: analyzed and interpreted the data; Hua Zhang, Yongzhen Mo, Weihong Jiang: contributed reagents, materials, analysis tools or data; Xiaotian Yuan, Benjian Zhang, Lai Meng: wrote the paper. Funding This research was funded by the National Natural Science Foundation of China (82171118), the Central South University graduate students independent exploration and innovation project (1053320222011), and the Natural Science Foundation of Hunan Province (2021JJ41027). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Data availability Data will be made available on request. Declarations Ethics approval and consent to participate The studies involving human participants were reviewed and approved by Xiangya hospital Research Ethics Committee of the Central South University. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article. Consent for publication All information was collected with the consent of the patient and approved by our institutional ethics department. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Hua Zhang, Email: entxy@126.com. Yongzhen Mo, Email: moyongzhen@csu.edu.cn. Weihong Jiang, Email: jiangwh68@126.com. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Figure 1. Quality control and cell type annotation of single-cell data. (A)-(D) Detected number of genes (nFeature), reads (nCount), mitochondrial gene percentage (percent.mt), and number of erythrocyte genes (percent.HB) for each of the 8 samples. (E)-(F) PCA analysis of samples before and after harmony correction, with different colors indicating the distribution of the 8 samples. (G) Expression of marker genes for major cell types. (H) Composition of major cell types in different pathological types of ACC. Supplementary Figure 2. Expression of marker proteins in ACC tumor cell lines and primary fibroblasts. CAFs express vimentin but not CK; MCAM+ myCAFs derived from the solid-type ACC specifically express MCAM, whereas CAFs derived from the non-solid type do not express MCAM. Supplementary Figure 3. Expression of angiogenic factors in CAFs from different sources. (A)–(E) Bar graphs comparing the protein expression levels of angiogenic factors in the culture supernatants of CAFs from different origins. Statistical analysis compares the overall mean values of two solid-derived MCAM+ CAFs with the overall mean values of three non-solid-derived MCAM- CAFs. nS represents non-solid and S represents solid, the same applies throughout. Significance: ****P<0.0001, **P<0.01, nsP≥0.05. Supplementary Figure 4. Quantitative Analysis of ChIP Assays for MEF2C Binding to Promoter Regions of Angiogenic Factors. (A)-(D) Panels A-D present the quantitative analysis results of ChIP experiments on the promoter regions of MEF2C with PDGFA, PDGFB, ANGPT1, and ANGPT2, respectively. The data for VEGFA's two targets are not shown due to absence of signals in both cases. Significance:**P<0.01, *P<0.05, nsP≥0.05. Supplementary Figure 5. Pro-angiogenic factor expression in S-CAFs after MEF2C knockdown. (A)-(E) Bar graphs comparing the protein expression levels of pro-angiogenic factors in the culture supernatants of S-CAFs before and after MEF2C knockdown. Statistical analysis compares the overall mean values of the two cell lines before and after knockdown. Significance: ****P<0.0001, ***P<0.001, **P<0.01,*P<0.05. Supplementary Material 2. Supplementary Material 3. Supplementary Material 4. Supplementary Material 5. Supplementary Material 6. Supplementary Material 7. Supplementary Material 8. Data Availability Statement Data will be made available on request.